Absolutely,
I never posted this original thread. I don't think its a case of MSB vs GILD. Gilead have very much moved their criteria intra and inter-trials. MSB has not. It has consistently set clear criteria for patients in the trials. Gilead has not. They have also changed the end-point. Honestly, just go the Gilead results and read them for yourself. Don't listen to me. Make your own mind up:
https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19
Gilead vs Mesoblast, page-275
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.000(0.00%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.13 | $1.373M | 1.202M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 30559 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 11447 | 6 |
View Market Depth
| Last trade - 12.44pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |